Overview

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
Ono Pharmaceutical Co. Ltd
Treatments:
Rivastigmine